TBWA
CRVS icon

Three Bridge Wealth Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Three Bridge Wealth Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,371
Closed -$327K – 90
2026
Q1 		$327K Hold
22,371
– – 0.09% 70
2025
Q4 		$172K Hold
22,371
– – 0.05% 90
2025
Q3 		$165K Hold
22,371
– – 0.04% 87
2025
Q2 		$89.5K Hold
22,371
– – 0.02% 123
2025
Q1 		$71.1K Hold
22,371
– – 0.02% 84
2024
Q4 		$120K Buy
+22,371
New +$167K 0.04% 93

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Three Bridge Wealth Advisors's CRVS Position: Q2 2026 in Review

Three Bridge Wealth Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q2 2026, closing a stake of 22,371 shares — an estimated $327K sold.

Three Bridge Wealth Advisors first reported a position in CRVS in Q4 2024 and held it in 6 quarters. The position peaked at $327K in Q1 2026. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Three Bridge Wealth Advisors reported no remaining Corvus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Three Bridge Wealth Advisors sold 22,371 Corvus Pharmaceuticals shares in Q2 2026, an estimated $327K.
  • Three Bridge Wealth Advisors first reported a position in Corvus Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • Three Bridge Wealth Advisors's Corvus Pharmaceuticals position peaked at $327K in Q1 2026.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Three Bridge Wealth Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.